PBI7 BUDGET IMPACT ANALYSIS OF INTRODUCTION OF BEVACIZUMAB BIOSIMILAR IN THE UNITED STATES FROM A PAYER PERSPECTIVE

Abstract

Authors

V. Ektare R. Liu J. Stephens A. Shelbaya J. Yang

Full Text Cite This Article
Back to Volume 23, Supplemental S1
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×